Literature DB >> 27900630

Current Delivery of Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery (CS/HIPEC) and Perioperative Practices: An International Survey of High-Volume Surgeons.

Allison H Maciver1, Eisar Al-Sukhni1, Jesus Esquivel2, Joseph J Skitzki1, John M Kane1, Valerie A Francescutti3.   

Abstract

BACKGROUND: Cytoreductive surgery and heated intraperitoneal chemotherapy (CS/HIPEC) is performed for selected indications at a limited number of specialized centers worldwide. Currently there is no standardized approach to the perioperative care process. We sought to capture current practices in the perioperative management of patients who undergo CS/HIPEC at high-volume centers.
METHODS: Surgeon members of the American Society of Peritoneal Surface Malignancies working at high-volume CS/HIPEC centers (>10 cases/year) were invited to complete an online survey. The survey included questions relating to preoperative preparation of patients, intraoperative practices, and postoperative care.
RESULTS: Ninety-seven surgeons from five continents completed the survey (response rate 55%). The majority (80%) practiced in academic environments. Most respondents (68%) indicated that a formal preoperative preparatory pathway for CS/HIPEC surgery existed at their centers, but few (26%) had used enhanced recovery protocols in this group of patients. Whereas the intraoperative technical practices of the CS/HIPEC procedure were relatively consistent across respondents, there was little agreement on pre- and postoperative care practices, including use of mechanical bowel preparation, nutritional supplementation, methods of perioperative analgesia, timing of physical therapy and ambulation, nasogastric tube and Foley removal, intravenous fluids, blood transfusion parameters, and postoperative use of deep-vein thrombosis prophylaxis and antibiotics.
CONCLUSIONS: Perioperative care practices for CS/HIPEC are widely variable nationally and internationally. Standardization of such practices offers an opportunity to incorporate evidence-based interventions and may enhance patient outcomes and improve care standards across all centers that offer this procedure.

Entities:  

Mesh:

Year:  2016        PMID: 27900630     DOI: 10.1245/s10434-016-5692-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

Review 1.  [Hyperthermic intraperitoneal chemotherapy].

Authors:  H Leebmann; P Piso
Journal:  Chirurg       Date:  2019-07       Impact factor: 0.955

2.  Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without HIPEC.

Authors:  Ankit Dhiman; Emily Fenton; Jeffrey Whitridge; Jennifer Belanski; Whitney Petersen; Sarah Macaraeg; Govind Rangrass; Ardaman Shergill; Dejan Micic; Oliver S Eng; Kiran Turaga
Journal:  Ann Surg Oncol       Date:  2021-05-05       Impact factor: 5.344

3.  Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement.

Authors:  Jason B Liu; Darryl Schuitevoerder; Charles C Vining; Yaniv Berger; Kiran K Turaga; Oliver S Eng
Journal:  Ann Surg Oncol       Date:  2020-07-29       Impact factor: 5.344

4.  Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study.

Authors:  Kevin M Turner; Mackenzie C Morris; Aaron M Delman; Dennis Hanseman; Fabian M Johnston; Jonathan Greer; Kara Vande Walle; Daniel E Abbott; Mustafa Raoof; Travis E Grotz; Keith Fournier; Sean Dineen; Jula Veerapong; Ugwuji Maduekwe; Anai Kothari; Charles A Staley; Shishir K Maithel; Laura A Lambert; Alex C Kim; Jordan M Cloyd; Gregory C Wilson; Jeffrey J Sussman; Syed A Ahmad; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2022-10-18       Impact factor: 3.267

5.  Anesthesia and Pain Management for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors in Children, Adolescents, and Young Adults.

Authors:  Doralina L Anghelescu; Christina-Lin Brown; Andrew J Murphy; Andrew M Davidoff; Paxton V Dickson; Evan S Glazer; Zachary E Stiles; Michael W Bishop; Luke Douthitt; Jeremiah L Deneve
Journal:  Ann Surg Oncol       Date:  2018-10-23       Impact factor: 5.344

6.  Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  June S Peng; Jessica LaPiano; Katy Wang; Kristopher Attwood; Joseph J Skitzki; John M Kane; Valerie A Francescutti
Journal:  Ann Surg Oncol       Date:  2021-08-12       Impact factor: 5.344

7.  Practice patterns, attitudes, and knowledge among clinicians regarding hyperthermic intraperitoneal chemotherapy and pressurized intraperitoneal aerosol chemotherapy: a national survey by Indian society of peritoneal surface malignancies (ISPSM).

Authors:  Sampige Prasanna Somashekhar; Kumar C Rohit; S V S Deo; Kyatsandra Rajagopal Ashwin
Journal:  Pleura Peritoneum       Date:  2020-08-31

8.  Nasogastric- vs. percutaneous gastrostomy tube for prophylactic gastric decompression after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Job P van Kooten; Nadine L de Boer; Marjolein Diepeveen; Cornelis Verhoef; Jacobus W A Burger; Alexandra R M Brandt-Kerkhof; Eva V E Madsen
Journal:  Pleura Peritoneum       Date:  2021-03-24

9.  Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons.

Authors:  Heon Jong Yoo; Jenny J Hong; Young Bok Ko; Mina Lee; Youjin Kim; Hye Young Han; Yong Jung Song; Myong Cheol Lim; Sang-Yoon Park
Journal:  World J Surg Oncol       Date:  2018-05-15       Impact factor: 2.754

10.  Antibiotic Prophylaxis for Surgical Site Infection in General Surgery: Oncological Treatments and HIPEC.

Authors:  Carlo Vallicelli; Federico Coccolini; Massimo Sartelli; Luca Ansaloni; Simona Bui; Fausto Catena
Journal:  Antibiotics (Basel)       Date:  2021-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.